Document is current
Any future updates will be listed below
-
Authors
DeNardo, David G
Galkin, Anna
Dupont, Jakob
Zhou, Lei
Bendell, Johanna
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04060342 at ClinicalTrials.govnct01346358 at ClinicalTrials.govDocuments that mention this clinical trial
388 Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors
https://doi.org/10.1136/jitc-2020-sitc2020.0388
389 Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2020-sitc2020.0389
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
https://doi.org/10.1136/jitc-2021-003005
nct02265536 at ClinicalTrials.govDocuments that mention this clinical trial
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
https://doi.org/10.1136/jitc-2021-003005
nct02713529 at ClinicalTrials.govDocuments that mention this clinical trial
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
https://doi.org/10.1136/jitc-2021-003005
nct01349036 at ClinicalTrials.govDocuments that mention this clinical trial
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
https://doi.org/10.1136/jitc-2021-003005
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors
https://doi.org/10.1136/jitc-2020-001006
nct01217229 at ClinicalTrials.govDocuments that mention this clinical trial
Co-evolution of glioma and immune microenvironment
https://doi.org/10.1136/jitc-2024-009175
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
https://doi.org/10.1136/jitc-2021-003005
nct03336216 at ClinicalTrials.govDocuments that mention this clinical trial
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
https://doi.org/10.1136/jitc-2021-003005
nct02371369 at ClinicalTrials.govDocuments that mention this clinical trial
Advances in the management of pancreatic cancer
https://doi.org/10.1136/bmj-2022-073995
Blood TCTP as a potential biomarker associated with immunosuppressive features and poor clinical outcomes in metastatic gastric cancer
https://doi.org/10.1136/jitc-2024-010455
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
https://doi.org/10.1136/jitc-2021-003005
nct03980041 at ClinicalTrials.govDocuments that mention this clinical trial
Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives
https://doi.org/10.1016/j.ejca.2016.04.022
Patient-reported Symptoms of Tenosynovial Giant Cell Tumors
https://doi.org/10.1016/j.clinthera.2016.03.008
ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT)
https://doi.org/10.2217/fon-2020-0307
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
https://doi.org/10.1136/jitc-2021-003005
nct03795610 at ClinicalTrials.govDocuments that mention this clinical trial
It takes two to TAM-go
https://doi.org/10.1136/gutjnl-2024-334506
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
https://doi.org/10.1136/jitc-2021-003005
nct03961698 at ClinicalTrials.govDocuments that mention this clinical trial
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
https://doi.org/10.1136/jitc-2021-003005
nct04060342 at ClinicalTrials.govDocuments that mention this clinical trial
It takes two to TAM-go
https://doi.org/10.1136/gutjnl-2024-334506
Lifting the innate immune barriers to antitumor immunity
https://doi.org/10.1136/jitc-2020-000695
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
https://doi.org/10.1136/jitc-2021-003005
Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment
https://doi.org/10.1136/jitc-2024-009160
Documents that mention this clinical trial
388 Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors
https://doi.org/10.1136/jitc-2020-sitc2020.0388
389 Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2020-sitc2020.0389
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
https://doi.org/10.1136/jitc-2021-003005
-
Funding
Funding for this research was provided by:
Gossamer Inc in collaboration with Merck & Co, Inc
- License Information
